Evidence map›Paper›PMID 38769902›Full record

ArticleCPT: pharmacometrics & systems pharmacology2024

Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias.

Alzahra Hamdan, Andrew C Hooker, Xiaomei Chen, Andreas Traschütz, Rebecca Schüle, ARCA Study Group, EVIDENCE‐RND consortium, Matthis Synofzik, Mats O Karlsson

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Spastic Ataxia Composite (SPAXCOM): A Scale to Evaluate the Progression of Subjects with Spasticity and Ataxia.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alzahra HamdanPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0002-3102-2707
Andrew C HookerPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2676-5912
Xiaomei ChenPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0002-0663-0532
Andreas TraschützDepartment of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-8165-5898
Rebecca SchüleDepartment of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-7781-2766
ARCA Study Group
EVIDENCE‐RND consortium
Matthis SynofzikDepartment of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-2280-7273
Mats O KarlssonPharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-1258-8297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Scale for the Assessment and Rating of Ataxia (SARA) is widely used for assessing the severity and progression of genetic cerebellar ataxias. SARA is now considered a primary end point in several ataxia treatment trials, but its underlying composite item measurement model has not yet been tested. This work aimed to evaluate the composite properties of SARA and its items using item response theory (IRT) and to demonstrate its applicability across even ultra-rare genetic ataxias. Leveraging SARA subscores data from 1932 visits from 990 patients of the Autosomal Recessive Cerebellar Ataxias (ARCA) registry, we assessed the performance of SARA using IRT methodology. The item characteristics were evaluated over the ataxia severity range of the entire ataxia population as well as the assessment validity across 115 genetic ARCA subpopulations. A unidimensional IRT model was able to describe SARA item data, indicating that SARA captures one single latent variable. All items had high discrimination values (1.5-2.9) indicating the effectiveness of the SARA in differentiating between subjects with different disease statuses. Each item contributed between 7% and 28% of the total assessment informativeness. There was no evidence for differences between the 115 genetic ARCA subpopulations in SARA applicability. These results show the good discrimination ability of SARA with all of its items adding informational value. The IRT framework provides a thorough description of SARA on the item level, and facilitates its utilization as a clinical outcome assessment in upcoming longitudinal natural history or treatment trials, across a large number of ataxias, including ultra-rare ones.

Indexed as

Cerebellar AtaxiaSeverity of Illness IndexAdolescentAdultAtaxiaChildDisease ProgressionFemaleHumansMaleMiddle AgedRare DiseasesRegistriesYoung Adult

Identifiers

PMID38769902
PMCPMC11330187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.